Date 08.03.2025
Marksans Pharma
Timeframe : Day Chart
Technical Remark :
1 There might be a lot of pain left in pharma sector as sector PE benchmark is 35 & a lot of stocks are riding over that despite of 30%-40% correction from top
2 At wave C 61% (marked in yellow) is very crucial, below that extension will be activated & could move down up to consolidation zone during wave 1
3 For Wave C completion conformation stock has to go above 200 EMA & stating point of wave B
Few Company Highlights :
Geography Wise Revenue Split - (Very critical amid tariff war situation)
United States & North America: 47.5%
United Kingdom & Europe: 39.5%
Australia & New Zealand: 9.2%
Rest of the World (CIS, MENA): 3.8%
1 Company is almost debt free
2 Promoter holding has decreased over last 3 years: -4.38%
3 The Company has 4 Manufacturing Units in Goa, UK, and USA
Regards,
Ankur
Marksans Pharma
Timeframe : Day Chart
Technical Remark :
1 There might be a lot of pain left in pharma sector as sector PE benchmark is 35 & a lot of stocks are riding over that despite of 30%-40% correction from top
2 At wave C 61% (marked in yellow) is very crucial, below that extension will be activated & could move down up to consolidation zone during wave 1
3 For Wave C completion conformation stock has to go above 200 EMA & stating point of wave B
Few Company Highlights :
Geography Wise Revenue Split - (Very critical amid tariff war situation)
United States & North America: 47.5%
United Kingdom & Europe: 39.5%
Australia & New Zealand: 9.2%
Rest of the World (CIS, MENA): 3.8%
1 Company is almost debt free
2 Promoter holding has decreased over last 3 years: -4.38%
3 The Company has 4 Manufacturing Units in Goa, UK, and USA
Regards,
Ankur
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.